Zusammenfassung
Das Endometriumkarzinom stellt in Mitteleuropa das häufigste Genitalmalignom dar. Bis jetzt existiert kein effektives Screening. Die uterine Blutungsstörung stellt meist ein Frühsymptom dar, das unmittelbar zur Diagnose eines Endometriumkarzinoms führt. Bei palpatorisch unauffälliger Cervix uteri und unauffälligen Parametrien erfolgt die extrafasziale Hysterektomie mit beidseitiger Adnexektomie. Eine Lymphadenektomie wird in jedem Fall von serösem und klarzelligem Karzinom empfohlen, des Weiteren beim endometrioiden Typ beginnend ab dem Stadium IB G3. Im Stadium I des Endometriumkarzinoms beträgt die Heilungsrate mit der alleinigen Operation 85–95 %. Eine adjuvante Radiotherapie reduziert die Anzahl lokoregionaler Rezidive, verbessert aber nicht das Gesamtüberleben. Eine adjuvante Chemotherapie, v. a. mit Carboplatin und Taxol, ist im Stadium III–IV indiziert. Auch im Stadium I–II kann eine Chemotherapie, v. a. bei ungünstiger Histologie, tiefer myometraner Invasion und/oder G3-Tumoren in Sequenz mit der Strahlentherapie des Beckens diskutiert werden. Nach Scheidenstumpfrezidiv beträgt das 3-Jahres-Überleben 69 % und nach pelvinem Rezidiv oder Fernmetastasen 13 %, wobei die Überlebensrate bei Patientinnen, die noch keine Radiotherapie erhalten hatten, deutlich besser ist als bei vorbestrahlten Patientinnen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Aalders J, Abeler V, Kolstad P, Onsrud M (1980) Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56:419–427
ASTEC Writing Committee (2009) Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373:125–136
Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD (2008) Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior. Obstet Gynecol Jul;112(1):64–70. https://doi.org/10.1097/aog.0b013e318176157c
Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ (2000) Stage IVB endometrial carcinoma. The role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:85–91
Bristow RE, Zahurak ML, Alexander CJ, Zellars RC, Montz FJ (2003) FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int J Gynecol Cancer 13:664–672
Brooks SE, Zhan M, Cote T, Baquet CR (2004) Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol 93:204–208
Chan JK, Urban R, Cheung MK, Shin JY et al (2007) Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients. Cancer 109:2454–2460
Chi DS, Welshinger M, Venkatraman ES, Barakat RR (1997) The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 67:56–60
Creasman W, Odicino F, Maisonneuve P et al (1998) Carcinoma of the corpus uteri. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostatics 1:35–61
Creutzberg CL, Putten WL van, Koper PC et al (2000) Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355:1404–1411
Creutzberg CL, Putten WL van, Koper PC et al (2003) PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 89:201–209
Creutzberg CL, Putten WL van, Warlam-Rodenhuis CC et al (2004) Postoperative radiation therapy in endometrial carcinoma trial. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the postoperative radiation therapy in endometrial carcinoma trial. J Clin Oncol 22:1234–1241
D’Angelo E, Prat J (2009) Uterine sarcomas: a review. Gynecol Oncol 116:131–139
DeMichele A et al (2008) Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. J Clin Oncol 26(25):4151–4159
Dreher E, Bronz L, Eggimann T, Maurer F, Munz E, Haller U (2004) Guideline: Abklärung von perimenopausalen Blutungsstörungen. Schweiz Ärztez 85:169–181
Evans MJ, Langlois NE, Kitchener HC, Miller ID (1995) Is there an association between long-term tamoxifen treatment and the development of carcinosarcoma (malignant mixed Mullerian tumor) of the uterus? Int J Gynecol Cancer 4:310–313
Fehr MK, Wight E, Haller U (1999) Stellenwert der Chemotherapie in der Behandlung des Endometriumkarzinoms. Gynakol Geburtshilfe Rundsch 39:110–120
Fujiwara H, Saga Y, Takahashi K, Ohwada M (2008) Omental metastases in clinical stage I endometrioid adenocarcinoma. Int J Gynecol Cancer 18:165–167
Galaal K, Bryant A, Fisher AD, Al-Khaduri M, Kew F, Lopes AD (2012) Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 12:9
Garg G, Kruger M, Christensen C, Deppe G, Toy EP (2011) Stage III uterine carcinosarcoma: 2009 international federation of gynecology and obstetrics staging system and prognostic determinants. Int J Gynecol Cancer Dec 21(9):1606–1612
Gerszten K, Faul C, Kounelis S, Huang Q, Kelley J, Jones MW (1998) The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol 68:8–13
Goff BA, Kato D, Schmidt RA et al (1994) Uterine papillary serous carcinoma: patterns of metastatic spread. Gynecol Oncol 54:264–268
Gonzalez Bosquet J, Terstriep SA, Cliby WA, Brown-Jones M, Kaur JS, Podratz KC, Keeney GL (2010) The impact of multi-modal therapy on survival for uterine carcinosarcomas. Gynecol Oncol Mar;116(3):419–423. https://doi.org/10.1016/j.ygyno.2009.10.053. (Epub 2009 Nov 5)
Hamilton CA, Cheung MK, Osann K, Chen L (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642–646
Hogberg T, Rosenberg P, Kristensen G (2007) A randomized phase-III study on adjuvant treatment with radiation chemotherapy in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 25:274s
Karlsson B, Granberg S, Wikland M et al (1995) Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding – a Nordic multicenter study. Am J Obstet Gynecol 172:1488–1494
Kaufmann M, Costa SD, Scharl A (Hrsg) (2003) Die Gynäkologie. Springer, Berlin
Maggi R, Lissoni A, Spina F (2006) Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95:266–271
Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, Yordan E, Brady MF (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 15(71) (4 Suppl.):1702–1709.
Mariani A, Dowdy S, Cliby W et al (2008) Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 109(2008):2011–2018
Mariani A, El-Nashar SA (2010) Lymphadenectomy in endometrial cancer. Which is the right question? Int J Gynecol Cancer 20:S52–S54
Martin-Hirsch P L, Jarvis G, Kitchener H, Lilford R (1999) Progestagens for endometrial cancer. Cochrane Database Syst Rev. (4). Art. No.: CD001040. https://doi.org/10.1002/14651858.cd001040
Mc Cluggage WG, Haller U, Kurman RJ, Kubik-Huch RA (2003) Mixed epithelial and mesenchymal tumours. In: Tavassoli FA, Devilee P (Hrsg) Tumours of the breast and female genital organs. IARC Press, Lyon, S 245–249
Minckwitz G von, Loibl S, Brunnert K (2002) Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer – a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer 38:2265–2271
Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol 40:55–65
Nemani D, Mitra N, Guo M, Lin (2008) Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol. Oct;111(1):82–88
Nout RA, Smit VT, Putter H et al; PORTEC Study Group (2010) Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 375:816–823
Onsrud M, Cvancarova M, Hellebrust T et al (2013) Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol 31:3951–3956
Panici BD, Basile S, Maneschi R et al (2008) Systematic pelvic lymphadenectomy versus no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 100:1707–1716
Pecorelli S (2009) Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 105:103–105
Pothuri B, Ramondetta L, Deavers M et al (2005) Prognosis of radiation-associated endometrial cancers compared to sporadic endometrial cancers. Gynecol Oncol 96:1004
Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA, Gynecologic Oncology Group Study (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44
Reed NS, Mangioni C, Malmstrom H et al (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an eortc gynaecological cancer group study (protocol 55874). Eur J Cancer 44:808–818
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371(9612):569–578. https://doi.org/10.1016/s0140-6736(08)60269-x. Review
Schünemann H, Jourdain M (1994) Double and triple neoplasms in endometrial carcinoma. Zentralbl Gynäkol 116:522–526
Senkus-Konfeka E, Konfeka T, Jassem J (2004) The effects of tamoxifen on the female genital tract. Cancer Treat Rev 30:291–301
Sherman ME, Devesa SS (2003) Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer Jul 1;98(1):176–186
Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY et al (1990) Carcinosarcoma (malignant mixed medodermal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases. Int J Gynecol Pathol 9:1–19
Slomovitz BM, Burke TW, Eifel PJ (2003) Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 91:463–469
Sreenan JJ, Hart WR (1995) Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19:666–674
Susumu N, Sagae S, Udagawa Y (2008) Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 108:226–233
Sutton G et al (2000) A Phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol; 79(2): 147–53
Tanner EJ, Leitao MM Jr, Garg K, Chi DS, Sonoda Y, Gardner GJ, Barakat RR, Jewell E (2011) The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol Dec;123(3):548–552
Thigpen JT, Brady MF, Alvarez RD et al (1999) Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the gynecologic oncology group. J Clin Oncol 17:1736–1744
Timmerman A, Opmeer BC, Khan KS et al (2010) Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol 116:160–167
Todo Y, Kato H, Kaneuchi M et al (2010) Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort study. Lancet 375:1165–1172
Yamada SD, Burger RA, Brewster WR, Anton D, Kohler MF, Monk BJ (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88:2782–2786
Weiterführende Literatur
Aapro MS, Wijk FH van, Bolis G et al (2003) European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14:441–448
Creasman W, Odicino F, Maisonneuve P et al (2001) Carcinoma of the corpus uteri. FIGO annual report on the results of treatment in gynaecological cancer. J Epidemiol Biostatics 6:45–86
Fleming GF, Filiaci VL, Bentley RC et al (2004a) Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group Study. Ann Oncol 15:1173–1178
Fleming GF, Brunetto VL, Cella D et al (2004b) Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:2159–2166
Jacobs I, Gentry-Maharaj A, Burnell M et al (2011) Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol 12(1):38–48
Kurman RJ, Kaminsky PF, Norris, HJ (1985) The behavior of endometrial hyperplasia. A longterm study of „untreated“ hyperplasia in 170 patients. Cancer 56(2):403–412
Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D (2009) Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study. J Clin Oncol 27:5337–5342
Morrow CP, Bundy BN, Homesley HD et al (1990) Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol 36:166–171
Randall ME, Brunetto G, Muss H et al (2003) Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 22:2
Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA (2003) Tumours of the uterine corpus. In: Tavassoli FA, Devilee P (Hrsg) Tumours of the breast and female genital organs. IARC Press, Lyon, S 221–232
Sorbe B et al (2009) Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 19(5):873–878.
Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C (1994) A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 12:1408–1414
Thigpen JT, Brady MF, Homesley HD et al (2004) Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 22:3902–3908
Wolfson AH et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI). cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107(2):177–85
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Imesch, P., Fehr, M.K., Fink, D. (2019). Maligne epitheliale Tumoren des Corpus uteri (einschließlich des Karzinosarkoms). In: Petru, E., Fink, D., Köchli, O., Loibl, S. (eds) Praxisbuch Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57430-0_3
Download citation
DOI: https://doi.org/10.1007/978-3-662-57430-0_3
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-57429-4
Online ISBN: 978-3-662-57430-0
eBook Packages: Medicine (German Language)